Disclosures for "XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy")
-
The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB). The institution of Dr. French has received research support from GW/One8 Foundation/FACES. The institution of Dr. French has received research support from NINDS. The institution of Dr. French has received research support from Xenon. The institution of Dr. French has received research support from Cerevel. The institution of Dr. French has received research support from FACES. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Epilepsy Study Consortium. Dr. French has received personal compensation in the range of $100,000-$499,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Aeovian that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Anavex that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Arkin Holdings that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Arvelle Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Athenen Therapeutics/Carnot Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Baergic Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Biohaven Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BioMarin Pharmaceutical Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BioXcel Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bloom Science Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with BridgeBio Pharma Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Camp4 Therapeutics Corporation that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerebral Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Clinical Education Alliance that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Coda Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Corlieve Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Eisai, that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Eliem Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Engage Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epalex that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Epihunter that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a SAB with Epiminder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Equilibre BioPharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Greenwich Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with GW Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Janssen Pharmaceutica that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Jazz Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Knopp Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Lipocine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with LivaNova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Longboard Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Lundbeck that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Marinus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mend Neuroscience that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Merck that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuCyte Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neumirna Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurocrine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neuroelectrics USA Corporation that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NxGen Medicine Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Ono Pharmaceutical Co that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Otsuka Pharmaceutical Development that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Ovid Therapeutics Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Paladin Labs Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Passage Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Pfizer that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LTY Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Rafa Laboratories Ltd that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with SK Life Sciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Sofinnova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Stoke that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Synergia Medica that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Takeda that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with UCB Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Ventus Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, steering committee with Xenon that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Xeris that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Zogenix that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Zynerba that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Biomarin that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, speaker with Angelini that is relevant to AAN interests or activities.
-
Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Otsuka. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cadent. Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Xenon. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aeterna. Dr. Porter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Passage Bio. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Longboard. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engrail. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Dr. Porter has received publishing royalties from a publication relating to health care. Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Epilepsy Study Consortium.
-
Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW . Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi . Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zogenix. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shackelford. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SKB Life Sciences. The institution of Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Arvelle. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PMI Life Sciences. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chiesi. Emilio Perucca has received publishing royalties from a publication relating to health care. Emilio Perucca has received publishing royalties from a publication relating to health care. Emilio Perucca has received publishing royalties from a publication relating to health care.
-
Martin Brodie has nothing to disclose.
-
Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals.
-
Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc..
-
Ms. Qian has received personal compensation for serving as an employee of Xenon Pharmaceuticals.
-
Constanza Luzon has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals.
-
Christopher Kenney has nothing to disclose.
-
Dr. Beatch has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc. Dr. Beatch has stock in Xenon Pharmaceuticals Inc. Dr. Beatch has received intellectual property interests from a discovery or technology relating to health care.